Antonio Antela

717 total citations
22 papers, 353 citations indexed

About

Antonio Antela is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Antonio Antela has authored 22 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 14 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Antonio Antela's work include HIV/AIDS drug development and treatment (16 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (14 papers). Antonio Antela is often cited by papers focused on HIV/AIDS drug development and treatment (16 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (14 papers). Antonio Antela collaborates with scholars based in Spain, France and Portugal. Antonio Antela's co-authors include Santiago Moreno, Ana Mariño, José Sanz, Rafael Rubio, Antonio Rivero, Juan Pasquau, Ignacio Suárez-Lozano, José A. Pérez‐Molina, Jordi Navarro and Jesús Troya and has published in prestigious journals such as The Lancet Infectious Diseases, American Journal of Kidney Diseases and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Antonio Antela

20 papers receiving 341 citations

Peers

Countries citing papers authored by Antonio Antela

Since Specialization

Citations

This map shows the geographic impact of Antonio Antela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Antela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Antela more than expected).

Fields of papers citing papers by Antonio Antela

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Antela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Antela. The network helps show where Antonio Antela may publish in the future.

Co-authorship network of co-authors of Antonio Antela

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Antela. A scholar is included among the top collaborators of Antonio Antela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Antela. Antonio Antela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	New horizons in the pharmaceutical care of HIV patients on long-term antiretroviral treatment. 2021 ·Farmacia Hospitalaria ·(unknown), Antonio Antela	1
2	Profilaxis preexposición al VIH en España: situación política y administrativa 2018 ·Enfermedades Infecciosas y Microbiología Clínica ·(unknown), Carlos Iniesta, (unknown), María José López Fuster, (unknown), Michael Meulbroek, (unknown), Melchor Riera, Antonio Antela, Santiago Moreno, David Dalmau, Antonio Rivero, (unknown), (unknown), Julia del Amo	4
3	Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study 2016 ·HIV Clinical Trials ·Eugénio Teófilo, (unknown), Birger Kuhlmann, Antonio Antela, Heribert Knechten, Jesús Santos, María Jesús Jiménez‐Expósito, (unknown)	2
4	Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study) 2016 ·Journal of Antimicrobial Chemotherapy ·José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero, Juan Pasquau, Ignacio Suárez-Lozano, Melchor Riera, Miriam Estébanez, Rosario Palacios, José Sanz, Jesús Troya, Ana Mariño, Antonio Antela, Jordi Navarro, Herminia Esteban, Santiago Moreno	48
5	The role of tenofovir alafenamide in future HIV management 2016 ·HIV Medicine ·Antonio Antela, Carlos Aguíar, Juliet Compston, (unknown), Marta Boffito, Patrick Mallon, (unknown), Giovanni Di Perri	40
6	Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial 2015 ·The Lancet Infectious Diseases ·José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero, Juan Pasquau, Ignacio Suárez-Lozano, Melcior Riera, Miriam Estébanez, Jesús Santos, José Sanz, Jesús Troya, Ana Mariño, Antonio Antela, Jordi Navarro, Herminia Esteban, Santiago Moreno	87
7	Eficacia de dolutegravir en pacientes naïve. Estudios SPRING-1, SPRING-2, SINGLE y FLAMINGO 2015 ·Enfermedades Infecciosas y Microbiología Clínica ·José Ignacio Bernardino, Antonio Antela	0
8	Nuke‐sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study 2014 ·Journal of the International AIDS Society ·(unknown), Antonio Antela, (unknown), Marta Díaz‐Menéndez, Pompeyo Viciana, (unknown), José Sanz, (unknown), J. Marta Moreno, José Hernández‐Quero, (unknown), (unknown)	7
9	Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial 2014 ·The Lancet Infectious Diseases ·Anton Pozniak, Martin Markowitz, Anthony Mills, Hans‐Juergen Stellbrink, Antonio Antela, Peré Domingo, Pierre‐Marie Girard, Keith Henry, (unknown), David Piontkowsky, Will Garner, Kirsten White, Bill Guyer	75
10	Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir‐boosted protease inhibitor‐based versus a nonnucleoside reverse transcriptase inhibitor‐based first‐line regimen 2014 ·HIV Medicine ·Inmaculada Jarrín, Beatriz Hernández‐Novoa, Belén Alejos, Ignacio de los Santos, José López‐Aldeguer, Melchor Riera, Félix Gutiérrez, Rafael Rubio, Antonio Antela, José Ramón Blanco, Santiago Moreno	5
11	Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study 2012 ·Current HIV Research ·Daniel Podzamczer, Estebán Martínez, Peré Domingo, Elena Ferrer, Pompeyo Viciana, Jordi Curto, Maria Jesús Pérez‐Elías, Antonio Ocampo, Ignacio de los Santos, Hernando Knobel, Vicente Estrada, Eugènia Negredo, Ferrán Segura, Joaquín Portilla, Esteban Ribera, (unknown), Antonio Antela, (unknown), (unknown), (unknown)	2
12	Long‐term efficacy and safety of atazanavir/ritonavir treatment in a cohort of treatment‐naïve HIV patients: an interim analysis of the REMAIN study 2012 ·Journal of the International AIDS Society ·Eugénio Teófilo, Heribert Knechten, Antonio Antela, (unknown), (unknown), (unknown), (unknown)	0
13	Tuberculous hepatic abscess appearing after liver transplantation in a patient with human immunodeficiency virus and hepatitis B and C virus co‐infection 2011 ·Transplant Infectious Disease ·(unknown), Antonio Antela, (unknown), E. Otero, Esther Molina, Evaristo Varó	5
14	Liver Toxicity After Switching or Simplifying to Nevirapine-Based Therapy Is Not Related to CD4 Cell Counts: Results of the TOSCANA Study 2010 ·HIV Clinical Trials ·Antonio Antela, Antonio Ocampo, (unknown), María Jesús López, Ana Mariño, Elena Losada, (unknown), (unknown), Juan Corredoira, (unknown), (unknown), Celia Miralles, (unknown), (unknown)	7
15	El papel de las combinaciones de antirretrovirales a dosis fijas en el tratamiento de la infección por VIH-1 2010 ·Enfermedades Infecciosas y Microbiología Clínica ·Josep M. Llibre, Antonio Antela, José Ramón Arribas, Peré Domingo, Josep M. Gatell, José López-Aldeguer, Fernando Lozano, Celia Miralles, José Moltó, Santiago Moreno, Enrique Ortega, Melcior Riera, Antonio Rivero, (unknown), Bonaventura Clotet	5
16	Liver Toxicity After Switching or Simplifying to Nevirapine-Based Therapy Is Not Related to CD4 Cell Counts: Results of the TOSCANA Study 2010 ·HIV Clinical Trials ·Antonio Antela, Antonio Ocampo, (unknown), María Jesús López, Ana Mariño, Elena Losada, (unknown), (unknown), Juan Corredoira, (unknown), (unknown), Celia Miralles, (unknown), (unknown)	3
17	[Recommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)]. 1998 ·PubMed ·Santiago Moreno, Jon Arrizabalaga, José María Gatell, Bonaventura Clotet, Koldo Aguirrebengoa, Antonio Antela, (unknown), Fernando Ballester Laguna, Miró Jm, I Ocaña, Rafael Rubio, Pompeyo Viciana, D Podzamczer	2
18	[Recommendations on antiretroviral treatment. The AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology]. 1998 ·PubMed ·Santiago Moreno, Jon Arrizabalaga, José María Gatell, B Clotet, Koldo Aguirrebengoa, Antonio Antela, (unknown), Fernando Ballester Laguna, Miró Jm, I Ocaña, Rafael Rubio, Pompeyo Viciana, D Podzamczer	6
19	Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy 1996 ·American Journal of Kidney Diseases ·Juan F. Navarro‐González, (unknown), C. Quereda, N. Gallego, Antonio Antela, Carmen Mora‐Fernández, (unknown)	33
20	Community Acquired Pneumonia Caused by <i>Chlamydia pneumoniae</i> Strain TWAR in Chronic Cardiopulmonary Disease in the Elderly 1991 ·Respiration ·Adalberto Pacheco, (unknown), Carlos Arocena, (unknown), Antonio Antela, Antonio Guerrero	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact